Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

计划入组 52 人 · 首次发布于 2019 年 8 月 6 日

Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)

计划入组 63 人 · 首次发布于 2018 年 8 月 22 日

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

计划入组 78 人 · 首次发布于 2010 年 6 月 30 日

Interferon alfa-1b

TMC-1B

ORL-1B

Celgene International II SARL

Switzerland

Meiragtx UK II Ltd.

Belgium

Generics Bidco II, LLC

United States

DelveInsight Report: Over 50 Pipeline Drugs in Development for Urothelial Carcinoma Treatment

Faron Updates Bexmarilimab IIT Portfolio: BLAZE Switches to Nivolumab, BEXAR Cleared in Sarcoma, FINPROVE Cohort Discontinued

Opthea Reports Positive Phase 1b DME Trial Results